James Adams, MD
Internal Medicine · Birmingham, ALNPI 1033164371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $117 and has fallen 83.7% since, to $19 in 2025.
Across 33 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$125
- Pfizer$107
- Novo Nordisk$97
- Abbott$68
- Boston Scientific$37
- Amgen$21
- plus $112 from 7 others
What the payments were for
- Food & beverage$566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $125 |
| Pfizer | 6 | $107 |
| Novo Nordisk | 6 | $97 |
| Abbott | 3 | $68 |
| Boston Scientific | 2 | $37 |
| Amgen | 1 | $21 |
| Novartis | 1 | $21 |
| GSK | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Pulmonx Corporation | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Vistapharm, Inc. | 1 | $12 |
How this compares
$566 in reported general payments places this provider in the 55th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Comfort Ez Pen NeedlePen Needle, Diabetic | 14 | $1,371 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $405 |
| Atorvastatin Calcium | 20 | $352 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $243 |
| Potassium Chloride | 14 | $243 |
| Gabapentin | 29 | $234 |
| Amlodipine Besylate | 15 | $206 |
| ClopidogrelClopidogrel Bisulfate | 13 | $129 |
| Levothyroxine Sodium | 15 | $125 |
| Carvedilol | 14 | $118 |
| Oxycodone Hcl | 11 | $79 |
| Famotidine | 11 | $73 |
| Tramadol Hcl | 11 | $71 |
| Furosemide | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Birmingham
- Ryan WeldonBirmingham$458K
- Robert LewisBirmingham$187K
- Thomas HuddleBirmingham$76K
- Jose VargasBirmingham$49K
- Donna FicoBirmingham$46K
- James SullivanBirmingham$39K
- Ross SchumacherBirmingham$26K
- Larry AlfordBirmingham$25K
- David WynneBirmingham$22K
- James CrenshawBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.